These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 31488319)
1. An Overview of Monoclonal Antibodies. Bayer V Semin Oncol Nurs; 2019 Oct; 35(5):150927. PubMed ID: 31488319 [TBL] [Abstract][Full Text] [Related]
2. Trends in cancer therapy: role of monoclonal antibodies. Schmidt KV; Wood BA Semin Oncol Nurs; 2003 Aug; 19(3):169-79. PubMed ID: 12962007 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in cancer immunotherapy. Kimiz-Gebologlu I; Gulce-Iz S; Biray-Avci C Mol Biol Rep; 2018 Dec; 45(6):2935-2940. PubMed ID: 30311129 [TBL] [Abstract][Full Text] [Related]
4. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
5. Antibodies in cancer immunotherapy. Karyampudi L; Knutson KL Cancer Biomark; 2010; 6(5-6):291-305. PubMed ID: 20938089 [TBL] [Abstract][Full Text] [Related]
6. Production of monoclonal antibodies in plants for cancer immunotherapy. Moussavou G; Ko K; Lee JH; Choo YK Biomed Res Int; 2015; 2015():306164. PubMed ID: 26550566 [TBL] [Abstract][Full Text] [Related]
7. Cationization of monoclonal antibodies: another step towards the "magic bullet"? Vaisitti T; Deaglio S; Malavasi F J Biol Regul Homeost Agents; 2005; 19(3-4):105-12. PubMed ID: 16602624 [TBL] [Abstract][Full Text] [Related]
8. Multi-specific antibodies for cancer immunotherapy. Jachimowicz RD; Borchmann S; Rothe A BioDrugs; 2014 Aug; 28(4):331-43. PubMed ID: 24638872 [TBL] [Abstract][Full Text] [Related]
9. Acute and Long-term Adverse Events Associated With Checkpoint Blockade. Davies M Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Pediatric Oncology: An Overview of Therapy Types and Nursing Implications. Warren CB Clin J Oncol Nurs; 2018 Dec; 22(6):649-655. PubMed ID: 30452014 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Taylor RP; Lindorfer MA Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480 [TBL] [Abstract][Full Text] [Related]
12. Adverse effects of the humanized antibodies used as cancer therapeutics. Klastersky J Curr Opin Oncol; 2006 Jul; 18(4):316-20. PubMed ID: 16721123 [TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Di Fede G; Bronte G; Rizzo S; Rolfo Cervetto C; Cocorullo G; Gulotta G; Bazan V; Russo A Expert Opin Biol Ther; 2011 Nov; 11(11):1433-45. PubMed ID: 21663530 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: a 10-year anniversary issue. Gregg M Immunotherapy; 2019 Feb; 11(2):61-62. PubMed ID: 30730267 [No Abstract] [Full Text] [Related]
16. Antibody-targeted immunotherapy for treatment of malignancy. White CA; Weaver RL; Grillo-López AJ Annu Rev Med; 2001; 52():125-45. PubMed ID: 11160771 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Cheng JD; Rieger PT; von Mehren M; Adams GP; Weiner LM Semin Oncol Nurs; 2000 Nov; 16(4 Suppl 1):2-12. PubMed ID: 11151455 [TBL] [Abstract][Full Text] [Related]
18. State of the art in anti-cancer mAbs. Chiavenna SM; Jaworski JP; Vendrell A J Biomed Sci; 2017 Feb; 24(1):15. PubMed ID: 28219375 [TBL] [Abstract][Full Text] [Related]